Coronary, Peripheral, and Neurovascular Guidewires – Performance Tests and Recommended Labeling

Draft Guidance for Industry and Food and Drug Administration Staff

DRAFT GUIDANCE

This guidance document is being distributed for comment purposes only.


You should submit comments and suggestions regarding this draft document within 60 days of publication in the Federal Register of the notice announcing the availability of the draft guidance. Submit electronic comments to https://www.regulations.gov. Submit written comments to Dockets Management Staff (HFA-305), Food and Drug Administration, 5630 Fishers Lane, Rm. 1061, Rockville, MD 20852. Identify all comments with the docket number listed in the notice of availability that publishes in the Federal Register.

For questions about this document, contact:
- Interventional Cardiology Devices Branch (ICDB/DCD) at (301) 796-6329
- Neurointerventional Devices Branch (NIDB/DNPMD) at (301) 796-2823
- Peripheral Interventional Device Branch (PIDB/DCD) at (301) 796-2520

When final, this guidance will supersede “Coronary and Cerebrovascular Guidewire Guidance” issued January 1995.
Preface

Additional Copies

Additional copies are available from the Internet. You may also send an e-mail request to CDRH-Guidance@fda.hhs.gov to receive a copy of the guidance. Please use the document number 16007 to identify the guidance you are requesting.
Table of Contents

I. Introduction ....................................................................................................................... 1
II. Background ....................................................................................................................... 2
III. Scope ................................................................................................................................. 2
IV. Premarket Submission Recommendations ................................................................. 2
   A. Device Description ............................................................................................. 3
   B. Predicate Comparison ......................................................................................... 3
   C. Biocompatibility ................................................................................................. 4
   D. Sterility ............................................................................................................... 5
   E. Pyrogenicity ........................................................................................................ 6
   F. Shelf Life and Packaging ................................................................................... 6
   G. Non-Clinical Bench Testing .............................................................................. 7
   H. Clinical Performance Testing ........................................................................... 14
   I. Labeling ............................................................................................................ 15
   V. Modifications ..................................................................................................... 17
Coronary, Peripheral and Neurovascular Guidewires - Performance Tests and Recommended Labeling

Draft Guidance for Industry and Food and Drug Administration Staff

This guidance represents the current thinking of the Food and Drug Administration (FDA or Agency) on this topic. It does not establish any rights for any person and is not binding on FDA or the public. You can use an alternative approach if it satisfies the requirements of the applicable statutes and regulations. To discuss an alternative approach, contact the FDA staff or Office responsible for this guidance as listed on the title page.

I. Introduction

This draft guidance document provides draft recommendations for 510(k) submissions for guidewires intended for use in the coronary, peripheral, and neurovascular. This draft document is intended to assist industry in designing and executing appropriate performance testing to support a premarket notification and provides recommendations for content and labeling to include in the submission. When final, this guidance will replace the “Coronary and Cerebrovascular Guidewire Guidance” document dated January 1995. This draft guidance is issued for comment purposes only.

For the current edition of the FDA-recognized standards referenced in this document, see the FDA Recognized Consensus Standards Database web site at https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfStandards/search.cfm. For more information regarding use of consensus standards in regulatory submissions, please refer to FDA guidance titled “Recognition and Use of Consensus Standards”.

FDA's guidance documents, including this guidance, do not establish legally enforceable responsibilities. Instead, guidances describe the Agency’s current thinking on a topic and should be viewed only as recommendations, unless specific regulatory or statutory requirements are cited. The use of the word should in Agency guidance means that something is suggested or recommended, but not required.

II. Background

Guidewires are used to facilitate the placement of therapeutic devices during percutaneous interventional procedures. In the context of this guidance, the guidewires being discussed are intended for use in the coronary, peripheral, and neurovasculature. There have been many technological advancements since the initial regulation of these devices and since the current final guidance on the topic was published. Therefore, updated information and additional clarity is needed regarding FDA’s recommendations for performance testing and labeling for a 510(k) for new or modified guidewires.

This document supplements other FDA documents regarding the specific content requirements and recommendations of a 510(k) submission. You should also refer to 21 CFR 807.87 and FDA’s guidance, “Format for Traditional and Abbreviated 510(k)s”.

III. Scope

The scope of this document is limited to guidewires indicated for use in the coronary, peripheral, and neurovasculature, regulated under 21 CFR 870.1330 and with product codes listed in the table below.

<table>
<thead>
<tr>
<th>Product Code</th>
<th>Regulation Number</th>
<th>Name</th>
</tr>
</thead>
<tbody>
<tr>
<td>DQX</td>
<td>21 CFR 870.1330</td>
<td>Wire, Guide, Catheter, Cardiovascular</td>
</tr>
<tr>
<td></td>
<td></td>
<td>(Coronary and Peripheral)</td>
</tr>
<tr>
<td>MOF</td>
<td>21 CFR 870.1330</td>
<td>Guide, Wire, Catheter, Neurovasculature</td>
</tr>
</tbody>
</table>

IV. Premarket Submission Recommendations

3 https://www.fda.gov/MedicalDevices/DeviceRegulationandGuidance/GuidanceDocuments/ucm084365.htm
A. Device Description

We recommend that you identify your device by the applicable regulation and product code described in Section III above and include the information described below.

As part of the device description, we also recommend that you identify all components and accessories and describe their function(s). In addition, we recommend that you provide the following information (if applicable to your device):

- description of technological characteristics;
- identification of configurations and models;
- listing of materials;
- identification of coatings;
- description of joints; and
- images or engineering drawings.

We recommend that you describe the technical and performance specifications of the device and include a brief description of the device design in this section. We also recommend the specifications include tolerance ranges, operating limitations and any other functional, physical, and environmental specifications of the device. If your submission includes multiple device models, we recommend that you identify all device models and configurations along with the device dimensions. You should also provide images or engineering drawings of the device and accessories that include dimensions and tolerances to fully describe and characterize the device and describe any unique device features (e.g., tip configuration, tip performance). If your device contains any joints (i.e., locations where adhesives, thermal fusion, or other joining methods are used for bonding components of the guidewire), we recommend that you identify the joint location and bonding method used.

Also as part of your device description, we recommend that you provide a list of all device components, their respective materials and their contact duration. We recommend identifying both the generic material(s) of construction and the unique material identifier(s). If your device includes coating(s), we recommend that you identify the coating name, chemical formulation, hydrophobicity or hydrophilicity, the coating purpose, thickness, length, location and how the coating is applied to the guidewire substrate. For additional labeling recommendations regarding coated devices, please see FDA’s draft guidance “Labeling Considerations for Intravascular Catheters, Wires, and Delivery Systems with Lubricious Coating” (https://www.fda.gov/downloads/MedicalDevices/DeviceRegulationandGuidance/Guidance Documents/UCM610630.pdf), which includes specific recommendations for this subset of guidewires.

B. Predicate Comparison

For devices reviewed under the 510(k) process, manufacturers must compare their new device to a similar legally marketed predicate device to support its substantial equivalence (21 U.S.C. 360c(i); 21 CFR 807.87(f)). This comparison should provide information to show how your device is similar to, and different from, the predicate. Side by side
comparisons, whenever possible, are desirable. See below for an example of how this
information may be organized. This table is not intended to represent an exhaustive list of
comparative parameters; ensure you provide all relevant device descriptive characteristics, as
outlined in Section IV.A. Device Description, above.

<table>
<thead>
<tr>
<th>Description</th>
<th>Your Device</th>
<th>Predicate Device (Kxxxxxx)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Indications for Use</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Wire Diameter</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Device Length</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tip Length</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tip Type and Shape</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tip Flexibility</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Wire Material</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Coating(s) Material, Length</td>
<td></td>
<td></td>
</tr>
<tr>
<td>and Location</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tip Material</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Accessories</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Packaging Configuration</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Sterilization Method</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Shelf Life</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

As part of your comparison, we recommend that you clearly explain the intended clinical
environment and indications for use of your device. The indications for use should identify
whether the device is intended to navigate into the peripheral, coronary or neurovasculature.
If your device contains any feature(s) that is unique to your device compared to the predicate,
we recommend that you clearly describe the feature(s), the location(s), and the operational
characteristics and provide an explanation as to why the differences do not raise different
questions of safety and effectiveness.

C. Biocompatibility

Significance
Guidewires contain patient-contacting materials, which, when used for their intended
purpose, (i.e., limited direct contact with circulating blood), may induce a harmful biological
response.

Recommendation
You should determine the biocompatibility of all patient-contacting materials present in your
device. If your device is identical in composition and processing methods to guidewires with
a history of successful use, you may reference previous testing experience or the literature, if
appropriate. For some device materials, it may be appropriate to provide a reference to either
a recognized consensus standard, or to a Letter of Authorization (LOA) for a device Master
File (MAF).
If you are unable to identify a legally marketed predicate device with similar location/duration of contact and intended use that uses the same materials as used in your device, we recommend you conduct and provide a biocompatibility risk assessment. The assessment should explain the relationship between the identified biocompatibility risks, the information available to mitigate the identified risks, and identify any knowledge gaps that remain. You should then identify any biocompatibility testing or other evaluations that were conducted to mitigate any remaining risks.

We recommend that you follow FDA’s guidance “Use of International Standard ISO-10993-1, ‘Biological evaluation of medical devices - Part 1: Evaluation and testing within a risk management process’” which identifies the types of biocompatibility assessments that should be considered and recommendations regarding how to conduct related tests.

Per ISO 10993-1: Biological evaluation of medical devices – Part 1: Evaluation and testing within a risk management process and Attachment A of FDA’s guidance on ISO-10993-1, guidewires are externally communicating devices with limited (< 24 hour) duration direct contact with the circulating blood. Therefore, the following endpoints should be addressed in your biocompatibility evaluation:

- cytotoxicity;
- sensitization;
- irritation/intracutaneous reactivity;
- acute systemic toxicity;
- material-mediated pyrogenicity;
- complement activation (SC5b-9 pathway is recommended and C3a pathway optional);
- in vivo thrombogenicity; and
- direct and indirect hemolysis.

The following additional considerations are recommended for guidewires. If novel materials are used, then genotoxicity testing may also be needed. Testing should be conducted with the largest surface area device model and worst-case exposure, if irradiation is used. Test samples should represent the final, sterilized device.

**D. Sterility**

**Significance**

 Depending on the indications for use, guidewires come in contact with blood or cerebrospinal fluid and should be adequately sterilized to minimize infections and related complications.

**Recommendation**

---

For guidewires labeled as sterile, we recommend that you provide information for the final, sterilized device in accordance with FDA’s guidance “Submission and Review of Sterility Information in Premarket Notification (510(k)) Submissions for Devices Labeled as Sterile”. 5

E. Pyrogenicity

Significance

Pyrogenicity testing is used to help protect patients from the risk of febrile reaction due to gram-negative bacterial endotoxins and/or chemicals that can leach from a medical device (e.g., material-mediated pyrogens).

Recommendation

To address the risks associated with the presence of bacterial endotoxins, guidewires should meet pyrogen limit specifications by following the recommendations outlined in FDA’s guidance “Submission and Review of Sterility Information in Premarket Notification (510(k)) Submissions for Devices Labeled as Sterile”. 5 You should also follow the recommendations in “Guidance for Industry Pyrogen and Endotoxins Testing: Questions and Answers”. 6 To address the risks associated with material-mediated endotoxins, follow the recommendations in FDA’s guidance “Use of International Standard ISO-10993, 'Biological Evaluation of Medical Devices Part 1: Evaluation and Testing'”. 7

For devices intended to be labeled as “non-pyrogenic,” we recommend that both the bacterial endotoxin and rabbit material-mediated pyrogen testing be conducted.

F. Shelf Life and Packaging

Significance

Shelf life testing is conducted to support the proposed expiration date through evaluation of the package integrity for maintaining device sterility and/or evaluation of any changes to device performance or functionality.

Recommendation

With respect to package integrity for maintaining device sterility, you should provide a description of the packaging, including how it will maintain the device’s sterility, and a description of the package integrity test methods, but not the package test data. We recommend that package integrity test methods include simulated distribution and associated

package integrity, as well as simulated (and/or real-time) aging and associated seal strength
testing, to validate package integrity and shelf life claims. We recommend you follow the
methods described in the FDA-recognized series of consensus standards AAMI/ANSI/ISO
11607-1: Packaging for terminally sterilized medical devices – Part 1: Requirements for
materials, sterile barrier systems and packaging and AAMI/ANSI/ISO 11607-2: Packaging
for terminally sterilized medical devices – Part 2: Validation requirements for forming,
sealing and assembly processes.

With respect to evaluating the effects of aging on device performance or functionality, shelf
life studies should evaluate the critical device properties to ensure it will perform adequately
and consistently during the entire proposed shelf life. To evaluate device functionality, we
recommend that you assess each of the bench tests described in Section IV.G. Non-Clinical
Performance Testing and repeat all tests that evaluate design components or characteristics
that are potentially affected by aging

We recommend that you provide a summary of the test methods used for your shelf life
testing, results and the conclusions drawn from your results. If you use devices subject to
accelerated aging for shelf life testing, we recommend that you specify the way in which the
devices were aged. We recommend that you age your devices as per the currently FDA
Barrier Systems for Medical Devices and specify the environmental parameters established to
attain the expiration date. For devices or components containing polymeric materials or
coatings, you should plan to conduct testing on real-time aged samples to confirm that the
accelerated aging is reflective of real-time aging. This testing can be conducted in parallel
with 510(k) review and clearance, with results documented to file in the design history file
(i.e., complete test reports do not need to be submitted to FDA).

G. Non-Clinical Bench Testing

The purpose of the non-clinical engineering testing is to ensure that the device performs as
intended under the specified conditions of use and demonstrates substantial equivalence to
the predicate device. The non-clinical performance testing recommended for each device’s
indications for use may vary based on its respective risk profile associated with the intended
target vasculature. FDA recommends that you provide the information below to evaluate the
material and performance characteristics of your final, sterilized device that represents the
worst-case design for each performance test. Where appropriate, the performance of the
proposed device should be compared to that of the primary predicate device. If a test listed in
Section IV.G. Non-Clinical Performance Testing is excluded from your submission, we
recommend that you provide a clinical and risk-based justification for its omission.
For information on recommended content and format of test reports for the testing described in this section, refer to FDA’s Draft guidance, “Recommended Content and Format of Test Reports for Non-Clinical Bench Performance Testing in Premarket Submissions”.

1. Pre-Conditioning

Prior to conducting the non-clinical performance testing, we recommend that you prepare the device per the instructions for use and then subject the device to clinically relevant pre-conditioning. Pre-conditioning may include simulated use in an anatomical model (as discussed in Section IV.G.2. Simulated Use Model) depending upon the worst-case scenario and the device feature/specification being evaluated. We recommend that you clinically justify pre-conditioning parameters used for each test, where applicable.

2. Simulated Use Model

The simulated use model may be used when conducting pre-conditioning or testing in simulated anatomy is recommended. Your anatomical model should be appropriately tortuous to represent the indicated target vasculature of the worst-case treated patient population. Critical features to be considered in selecting the appropriate model include lumen diameter, bend radii, bend reversals, number of bends, tracking length, and coefficient of friction of tracking materials (e.g., polyurethane, silicone, Teflon, glass latex or native vessel). We recommend that your anatomical model be three-dimensional in order to best represent the human anatomy. Furthermore, it should appropriately model the various anticipated curvatures the device will encounter from all of the proposed access sites. An example of a recommended tracking fixture is described in Figure X2.4 of ASTM F2394: Standard Guide for Measuring Securement of Balloon Expandable Vascular Stent Mounted on Delivery System, which is used for devices intended to navigate the coronary arteries. We recommend providing the following information regarding your simulated use model in your submission:

• materials of construction;
• images of model(s) and engineering diagram(s); and
• clinical rationale for the chosen model.

When describing your simulated use model(s), we recommend that you identify the materials of construction of the model and include images and engineering diagrams that include dimensions (e.g., lengths, tubing diameters, radii of bend). We also recommend that a clinical rationale supporting the selection of the anatomical model parameters include a review of available imaging data or literature regarding the anatomy of the intended population. In addition, for devices with neurovascular indications, your simulated use model should be as tortuous as the relevant vasculature included in your instructions for use. Specifically, we

---

8 Available at https://www.fda.gov/downloads/MedicalDevices/DeviceRegulationandGuidance/GuidanceDocuments/UCM606051.pdf. When final, this guidance will represent FDA’s current thinking on the recommended content and format of test reports for non-clinical bench performance testing in premarket submissions.
recommend that you use a full anatomical model including entry at the femoral artery to the intended target location in the neurovasculature. Simulating worst-case tortuosity, your full anatomical model should include, at a minimum, the Internal Carotid Artery (ICA) siphon, two (2) 180-degree turns and two (2) 360-degree turns.

3. Dimensional Verification

Significance
Accurate device dimensions help the physician to select appropriate product sizes. They can also affect the functional behavior of the device.

Recommendation
We recommend providing dimensional specifications and tolerances for the device as manufactured. The tolerances chosen should be based on risk and should have an appropriate clinically or scientifically relevant justification. We recommend using a calibrated tool to verify each dimension. At a minimum, the length and outer diameter should be measured and reported. If applicable, tip length, coating length, or other guidewire features should also be reported.

4. Visual Inspection

Significance
Guidewire defects, including kinks, cracks, deformations or debris, can contribute to clinical complications, affecting the safety and performance of the device.

Recommendation
We recommend testing to ensure that the devices are free of extraneous matter and process and surface defects that could cause trauma to the vessels during use. If the device is coated, the coating should appear uniform. We recommend examining the devices with a minimum 2.5X magnification. This test may be conducted independently or in conjunction with another performance test if performed prior to performance testing to represent the as-manufactured product. Please note that for coated devices, visual inspection alone at 2.5X magnification is insufficient to evaluate the coating integrity and additional test considerations should be followed (see Section IV.G.10. Coating Integrity).

5. Simulated Use

Significance
Use of the device in a simulated use model, in combination with other interventional devices, as appropriate, can provide more clinically relevant information about its performance than isolated bench top performance testing.

Recommendation
We recommend that you use your device in combination with ancillary devices (e.g., introducer, guiding catheter) according to the instructions for use and track the device through the simulated use model multiple times. Please see Section IV.G.2 Simulated Use Model for recommendations in developing your model. You should report observations
regarding compatibility with secondary devices, appropriate preparation, and the maneuverability of the device through the simulated use model and the integrity of the device prior to, during, and after use. You should identify the minimum diameter catheter that is compatible with your guidewire and include this in the device labeling. This test may be conducted in conjunction with other tests when appropriately justified.

6. Tensile Strength

Significance
Joint failure could lead to device failure and/or vessel damage.

Recommendation
We recommend testing the strength of each joint to failure. Prior to testing we recommend that the samples are prepared per the instructions for use and then pre-conditioned as needed to simulate worst case conditions and tracked through a simulated use model. Tensile strength testing should demonstrate that your device is capable of withstanding tensile forces greater than those expected in clinical use. When setting your acceptance criteria, we recommend that you consider testing the predicate device concurrently or determine the theoretical force based on clinical information. When the acceptance criteria are established, a clinical basis for their appropriateness should be included in your protocol. Because the strain rate used may affect the resulting data, and thus, the acceptability of the acceptance criteria and results, we also recommend that you report the strain rate used to test each sample and justify this rate. FDA recommends using a rate that can be shown to be clinically relevant (i.e., a similar rate at which the guidewire would be pulled in order to be withdrawn from the vasculature).

7. Tip Pull

Significance
Tip detachment may adversely impact clinical performance (e.g., result in distal embolization).

Recommendation
For guidewires that contain one or more joints at the distal tip (e.g., spring or coil tips), we recommend evaluating the tensile force to separate the distal tip from the guidewire. Prior to testing, we recommend that the samples are prepared per the instructions for use and then pre-conditioned as needed to simulate worst case conditions and tracked through a simulated use model.

8. Torque Strength

Significance
Inability to withstand torsional forces typical of clinical use may lead to device failure and/or vessel damage.
Recommendation
We recommend that you prepare the samples per the instructions for use, pre-condition as needed to simulate worst case conditions, and track each device through a simulated use model. With the device in the simulated use model, we recommend that movement of the distal end of the device be constrained and the proximal end of the guidewire be rotated until failure. We recommend that you report the number of rotations to failure and the failure mode for each device tested.

9. Torqueability

Significance
An inability of the distal tip to respond to manipulations made at the proximal end may adversely impact clinical performance (e.g., whipping effects may cause vessel damage and/or inability to navigate vessels).

Recommendation
We recommend that you prepare the samples per the instructions for use, pre-condition as needed to simulate worst case conditions, and track each device through a simulated use model. With the sample in the simulated use model and the distal end unconstrained, we recommend that you rotate the proximal end of the guidewire. You should report the rotational input to the resulting distal rotation at 90-degree intervals (with a minimum of 360-total-degrees in one direction) and calculate a proximal-to-distal rotational ratio for each sample.

10. Coating Integrity

Significance
Coating separation (i.e., peeling, flaking, shedding delamination and/or sloughing off) or degradation may adversely impact clinical performance (e.g., result in inflammation at access site, pulmonary embolization, pulmonary infarct, myocardial embolization, myocardial infarct, embolic stroke, cerebral infarct, tissue necrosis, or death).

Recommendation
Coating integrity testing is a characterization test; therefore, quantitative acceptance criteria are not anticipated. However, you should provide an interpretation of the data collected before and after subjecting the device to simulated use testing in a representative tortuous model. We recommend assessing the device for any unintended coating delamination or degradation during simulated use. You should provide representative images (using scanning electron microscopy and/or optical microscopy) of the coated surface pre- and post-simulated use testing. Images should include multiple magnifications (40X-500X) in order to detail any coating defect. If your coating is clear, it may be beneficial to dye the coating prior to simulated use in order to allow for proper visualization. We recommend that you conduct the coating integrity testing simultaneously with the particulate evaluation as described in Section IV.G.11. Particulate Evaluation to assess the origin, quantity, and size of particulates that may be removed from your device during simulated use. If your device contains coating anomalies, you should provide a scientific rationale explaining why the coating anomalies do not pose a safety risk.
11. Particulate Evaluation

**Significance**
Particulate generation during clinical use may result in serious adverse events including pulmonary embolism, pulmonary infarction, myocardial embolism, myocardial infarction, embolic stroke, tissue necrosis and death; therefore, guidewires intended to navigate the coronary vasculature or neurovasculature pose the greatest clinical risk and should be evaluated for particle generation along with coating integrity assessment in a representative simulated use model. If your device is intended to only navigate the peripheral vasculature and the coating integrity evaluation identified coating defects that may raise additional clinical concerns, particulate evaluation may be needed to address potential safety concerns.

**Recommendation**
To accurately account for particulates generated during the use of your device, the particles should be characterized after simulated use. We recommend that the number of particulates generated at each evaluation be quantified and characterized by size and count using a validated method (e.g., light obscuration, light refraction) under continuous flow conditions to simulate blood flow. Specifically, we recommend that the total number of particulates be reported in the following size ranges: ≥10µm, ≥25µm, and at the largest size for which validation yields ≥75% recovery. At a minimum, the largest size should be ≥50µm. For devices indicated for use in the neurovasculature, and for particulates that are greater than 50 µm, we recommend that you distinguish, by percentage, the amount that are ≥200 µm, ≥500 µm and ≥1000 µm, if those measurement methods are available, as these larger sized particulates pose a greater embolic risk.

Appropriate precautions should also be implemented to ensure that the particles are suspended during particle counting and sizing to minimize artifacts from the test system. For further guidance on particulate evaluation, please refer to Section VIII.A.13. of FDA Guidance for Industry and FDA Staff, “Class II Special Controls Guidance Document for Certain Percutaneous Transluminal Coronary Angioplasty (PTCA) Catheters” ([https://www.fda.gov/MedicalDevices/DeviceRegulationandGuidance/GuidanceDocuments/ucm225145.htm](https://www.fda.gov/MedicalDevices/DeviceRegulationandGuidance/GuidanceDocuments/ucm225145.htm)).

If the particulate evaluation raises safety concerns, then chemical characterization may be needed to identify the particulate source(s).

12. Lubricity

**Significance**
Lubricious coatings may be incorporated to decrease frictional forces experienced when navigating the target vasculature, and the functionality and performance of these coatings should be demonstrated.

**Recommendation**
We recommend that you characterize the drag force of the coating (e.g., pinch test) after the samples are prepared per the instructions for use and then pre-conditioned as needed to
simulate worst case conditions. As part of this assessment, you should also visually inspect
the coating before and after testing for coating delamination, flaking, etc., and report your
observations.

13. Corrosion Resistance

Significance
Guidewire corrosion can cause or contribute to premature device failure. In addition,
corrosion byproducts may be toxic or cause other adverse biological and tissue responses.

Recommendation
We recommend that any metallic component of the device be examined for signs of
corrosion after an immersion test (e.g., exposure of the device to a series of saline baths at
room temperature, boiling, and 37°C beyond the maximum expected clinical use duration).
For more information regarding recommendations of methodology for this testing, please
refer to the currently recognized version of ISO 10555-1: Intravascular catheters – Sterile
and single-use catheters – Part 1: General requirements, Annex A. Although this standard
has been written for intravascular catheters, the method used to evaluate corrosion resistance
is applicable to guidewires.

14. Kink Resistance

Significance
Guidewires may be subjected to bending forces during use, and an inability to withstand
forces that are typical of clinical use could lead to device failure and/or vessel damage.

Recommendation
Your device should demonstrate resistance to kinking (and other failure modes) when bent
around anatomically relevant radii. The samples should be prepared per the instructions for
use and then pre-conditioned as needed to simulate worst case conditions. To evaluate the
resistance to kinking, you should track each sample through a simulated use model where
each sample is bent around mandrels of decreasing radii until failure (e.g., kink, deformation,
fracture) or to the smallest bend radii expected during clinical use. This evaluation should
account for all joints. When reporting the results, you should identify the mandrel sizes
tested, which mandrel caused device failure, the location of failure and the type of failure
observed.

15. Tip Flexibility

Significance
Safe and successful navigation through tortuous vessels relies on the mechanical properties
of the guidewire tip. Inappropriately designed guidewire tips may result in vessel perforation,
dissection and/or other vessel damage.

Recommendation
After the samples are prepared per the instructions for use and then pre-conditioned as needed to simulate worst case conditions, we recommend that you identify the force that induces buckling deformation when the device is held at 5, 10 and 20 mm from the distal tip.

16. Radiopacity

Significance
Insufficient radiopacity could impede safe and appropriate usage of the device as it will not be clearly visible during use.

Recommendation
We recommend choosing a sample size greater than 1 (1 < N ≤ 5) to ensure that the radiopaque markers are visible using clinical imaging techniques. We recommend a qualitative or quantitative measure of radiopacity, wherein the guidewire is compared to a standard material or predicate device as a control via real-time or plain film x-ray. We encourage the use of *in-vitro* phantoms or equivalent models, but will also consider data from images of animal studies. We recommend including high-quality images of the guidewires and the control(s) in your submission.

If the guidewire is indicated for the neurovasculature, we recommend radiopacity testing be conducted through the skull of an animal model or through a representative phantom. The skull presents additional attenuation of the x-ray signal, making imaging more challenging. Alternatively, a justification for why the skull was not included should be provided.

H. Clinical Performance Testing

Significance: In some cases, pre-clinical evaluation does not fully characterize all clinical experience, outcomes, and risks. In such cases, we recommend that you conduct in vivo (i.e., clinical) studies to evaluate device safety and effectiveness for new and modified guidewires.

Recommendation:
Clinical evidence is generally unnecessary for most guidewires; however, such testing may be requested in situations such as the following:
- indications for use in complex clinical scenarios (e.g., crossing chronic total occlusions (CTOs)) of the coronary and peripheral arteries;
- cases where engineering and/or animal testing raise issues that warrant further evaluation with clinical evidence;
- indications for use dissimilar from legally marketed devices of the same type; or
- new technology, i.e., technology different from that used in legally marketed devices of the same type, yet does not raise different questions of safety or effectiveness.

We will consider alternatives to clinical testing when the proposed alternatives are supported by an adequate scientific rationale. If a clinical study is needed to demonstrate substantial equivalence, i.e., conducted prior to obtaining 510(k) clearance of the device, the study must be conducted under the Investigational Device Exemptions (IDE) regulation, 21 CFR Part 812. Generally, FDA believes guidewires addressed by this guidance document are
significant risk devices subject to all requirements of 21 CFR 812. See the FDA Guidance titled, “Significant Risk and Nonsignificant Risk Medical Device Studies”. In addition to the requirements of Section 21 CFR 812, sponsors of such trials must comply with the regulations governing institutional review boards (21 CFR Part 56) and informed consent (21 CFR Part 50).

In some cases, “real-world data” (RWD) may be used to support expansion of the indication for a device for which 510(k) clearance has already been obtained. Whether the collection of RWD for a legally-marketed device requires an IDE depends on the particular facts of the situation. Specifically, if a cleared device is being used in the normal course of medical practice, an IDE would likely not be required. For additional information regarding this topic, please refer to the FDA Guidance entitled “Use of Real-World Evidence to Support Regulatory Decision-Making for Medical Devices”.

I. Labeling

The premarket notification must include proposed labeling in sufficient detail to satisfy the requirements of 21 CFR 807.87(e). Proposed labels and labeling, sufficient to describe guidewires, their intended use, and the directions for use must be provided.

As a prescription device, guidewires are exempt from having adequate directions for lay use required under section 502(f)(1) of the Federal Food, Drug and Cosmetic Act (FD&C Act) (21 U.S.C. § 352(f)(1))) as long as the conditions in 21 CFR 801.109 are met. For instance, labeling must include adequate information for the intended user of the device, including indications, effects, routes, methods, frequency and duration of administration and any relevant hazards, contraindications, side effects and precautions (21 CFR 801.109(d)).

The instructions for use or package insert should include the following information. The list below is not intended to be exhaustive of all the labeling requirements under part 801.

For additional recommendations regarding coated devices, please see FDA’s draft guidance “Labeling Considerations for Intravascular Catheters, Wires, and Delivery Systems with Lubricious Coating” (https://www.fda.gov/downloads/MedicalDevices/DeviceRegulationandGuidance/GuidanceDocuments/UCM610630.pdf), which includes specific labeling recommendations for this subset of guidewires.

Contains Nonbinding Recommendations

Draft – Not for Implementation

1. Device Description

We recommend that you include a description of the guidewire identifying the important components and the functions of each such as the length, outer diameter along the length including transition zones, tip shape, coating location(s) and characteristics (e.g., hydrophobic or hydrophilic), if applicable.

2. Indications for Use Statement

The indications for use described in the labeling should be supported by information in the 510(k) submission and clearly identify any specific regions of the vasculature.

3. Contraindications

We recommend including contraindications to describe situations in which there are known hazards or risks, as applicable, in the instructions for use. If you believe there are no known contraindications, please state “none known”.

4. Warnings

We recommend including the following warnings, as applicable, in the instructions for use. Sample language is provided in italics. If you believe any of these warnings are not applicable to your device, please provide a justification for each omission.

- A warning statement regarding the indications for which the device has been confirmed to perform as intended, such as the following: “The safety and effectiveness of the device has not been established or is unknown in vascular regions other than those specifically indicated.” For example, if a specific guidewire is only indicated for peripheral vascular use based on the information provided in the 510(k) submission, the device should include a warning that the safety and effectiveness of the device has not been established in the coronary vasculature or neurovasculature.

- A warning against reuse or re-sterilization of the device, which could affect non-metallic components, such as “This device is intended for single use. Do not reuse or re-sterilize.”

- A warning statement about the unestablished safety and effectiveness of a reprocessed device intended for multiple uses. For example, “The safety and effectiveness of this device has not been established after being reprocessed for multiple uses.”

- A warning statement about the unestablished safety and effectiveness of the subject device’s use with atherectomy devices.

5. Directions for Use

We recommend that you provide specific directions for use of the guidewire. If your device contains a coating(s), then the directions for use should clearly explain how to properly prepare the device prior to clinical use.
V. Modifications

In accordance with 21 CFR 807.81(a)(3), a device modification “that could significantly affect the safety or effectiveness of the device” or represents “a major change or modification in the intended use of the device” requires a new 510(k). FDA has determined that any one of the modifications listed below would likely require a new 510(k). The changes or modifications listed below would likely require submission of a new 510(k). Note that this list is not exhaustive but provides examples of modifications that will generally require submission of a new 510(k). For additional details, please see FDA guidance “Deciding When to Submit a 510(k) for a Change to an Existing Device”.\(^\text{11}\)

Such changes or modifications include:

- **Guidewire Material** – A change in core guidewire material that has not been previously used in its indicated vasculature could significantly affect both safety and effectiveness of the device by altering the biocompatibility risk profile or device performance.

- **Coating(s) Location, Material, Amount, or Processing** – A change in the coating composition, location, and the processes used to apply the coating could significantly affect both safety and effectiveness of the device by altering the biocompatibility risk profile and/or device performance.

- **Dimensions Not Previously Cleared** – A change to a critical dimensional characteristic of the guidewire that is beyond guidewires previously cleared could significantly affect both safety and effectiveness by significantly affecting the performance risk profile.

- **Tip Configuration** – A change to the tip shape, material, or adhesion process could significantly affect both the safety and effectiveness of the device because of a change to the known risk of tip detachment and the ability of the guidewire to properly navigate the intended vasculature.

- **Additional Vasculature** – A change in the target vasculature could significantly affect both safety and effectiveness due to new or altered risks associated with different clinical conditions than those previously addressed in prior submissions.

FDA believes that the following changes or modifications would likely not require submission of a new 510(k):

- minor changes to the device packaging (e.g., hard copy of the Instructions for Use is replaced by an electronically available copy);

- an extension of shelf life implemented according to the test protocols previously reviewed under the cleared submission; or

- a dimensional change within the existing specification tolerance.

---